Prothena Corporation plc logo
Prothena Corporation plc PRTA
$ 8.89 1.54%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Prothena Corporation plc Balance Sheet 2011-2026 | PRTA

Annual Balance Sheet Prothena Corporation plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-567 M -278 M -353 M -376 M -365 M -336 M -371 M -294 M -177 M -125 M -

Long Term Debt

8.23 M 10.7 M - 6.39 M 12.3 M - - - - - - - - -

Long Term Debt Current

2.61 M 1.11 M 6.47 M 5.94 M 5.51 M 5.1 M - - - - - - - -

Total Non Current Liabilities

11.7 M 78.1 M 85.8 M 110 M 123 M 129 M 161 M 51.8 M 53.5 M 2.35 M 2.19 M 1.73 M 1.06 M 1.65 M

Total Current Liabilities

48.5 M 56.9 M 50.1 M 33.5 M 25.8 M 17.7 M 14.9 M 37.4 M 41.1 M 22.2 M 12 M 7.41 M - -

Total Liabilities

60.2 M 135 M 136 M 143 M 149 M 146 M 176 M 89.1 M 94.6 M 24.6 M 14.2 M 9.14 M 2.8 M 10.1 M

Deferred Revenue

8.85 M - 11.4 M 7.66 M 110 M - - - - - - - - -

Retained Earnings

-1.1 B -980 M -833 M -716 M -783 M -672 M -598 M -442 M -289 M -129 M -48.5 M -41.3 M -345 K -

Total Assets

547 M 696 M 758 M 609 M 333 M 419 M 499 M 496 M 460 M 385 M 304 M 182 M 129 M 3.62 M

Cash and Cash Equivalents

471 M 619 M 710 M 579 M 295 M 376 M 428 M 418 M 387 M 371 M 294 M 177 M 125 M -

Book Value

487 M 561 M 622 M 466 M 184 M 273 M 323 M 407 M 365 M 361 M 290 M 173 M 126 M -6.44 M

Total Shareholders Equity

487 M 561 M 622 M 466 M 184 M 273 M 323 M 407 M 365 M 361 M 290 M 173 M 126 M -6.44 M

All numbers in USD currency

Quarterly Balance Sheet Prothena Corporation plc

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

6.2 M 6.93 M 7.58 M 8.23 M 8.88 M 9.54 M 10.1 M 10.7 M 8.92 M - - - 1.65 M 3.28 M 4.83 M 6.39 M 7.92 M 9.43 M 10.9 M 12.3 M 12.3 M 12.3 M 12.3 M 17.8 M 17.8 M 17.8 M 17.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

6.2 M 6.93 M 9.2 M 11.7 M 14.5 M 16.9 M 77.5 M 78.1 M 76.3 M 67.4 M 85.3 M 85.8 M 99.2 M 102 M 106 M 110 M 113 M 95.3 M 122 M 123 M 123 M 123 M 123 M 129 M 129 M 129 M 129 M 161 M 161 M 161 M 161 M 51.8 M 51.8 M 51.8 M 51.8 M 53.5 M 53.5 M 53.5 M 53.5 M 2.35 M 2.35 M 2.35 M 2.35 M 2.19 M 2.19 M 2.19 M 2.19 M 1.73 M 1.73 M 1.73 M - - - - - - - - -

Total Liabilities

57.6 M 74.7 M 57.7 M 60.2 M 60.9 M 63.6 M 121 M 135 M 130 M 139 M 134 M 136 M 150 M 142 M 143 M 143 M 142 M 148 M 145 M 149 M 149 M 149 M 149 M 146 M 146 M 146 M 146 M 176 M 176 M 176 M 176 M 89.1 M 89.1 M 89.1 M 89.1 M 94.6 M 94.6 M 94.6 M 94.6 M 24.6 M 24.6 M 24.6 M 24.6 M 14.2 M 14.2 M 14.2 M 14.2 M 9.14 M 9.14 M 9.14 M 9.14 M 2.8 M 2.8 M 2.8 M 2.8 M - - - -

Deferred Revenue

2.68 M 5.1 M 7.9 M 8.85 M 8.83 M 8.02 M - - 316 K 25.1 M 9.32 M 11.4 M 9.66 M 9.82 M 8.84 M 7.66 M 7.2 M 24.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.32 B -1.29 B -1.16 B -1.1 B -1.04 B -985 M -1.05 B -980 M -913 M -934 M -880 M -833 M -839 M -794 M -752 M -716 M -683 M -792 M -820 M -783 M -783 M -783 M -783 M -672 M -672 M -672 M -672 M -598 M -598 M -598 M -598 M -442 M -442 M -442 M -442 M -289 M -289 M -289 M -289 M -129 M -129 M -129 M -129 M -48.5 M -48.5 M -48.5 M -48.5 M -41.3 M -41.3 M -41.3 M -41.3 M -345 K -345 K -345 K -345 K - - - -

Total Assets

353 M 399 M 495 M 547 M 595 M 646 M 623 M 696 M 747 M 721 M 742 M 758 M 554 M 550 M 581 M 609 M 633 M 436 M 380 M 333 M 333 M 333 M 333 M 419 M 419 M 419 M 419 M 499 M 499 M 499 M 499 M 496 M 496 M 496 M 496 M 460 M 460 M 460 M 460 M 385 M 385 M 385 M 385 M 304 M 304 M 304 M 304 M 182 M 182 M 182 M 182 M 129 M 129 M 129 M 129 M - - - -

Cash and Cash Equivalents

331 M 371 M 418 M 471 M 519 M 564 M 547 M 619 M 671 M 659 M 686 M 710 M 496 M 509 M 543 M 579 M 600 M 400 M 343 M 298 M 295 M 295 M 295 M 376 M 376 M 376 M 376 M 428 M 428 M 428 M 428 M 418 M 418 M 418 M 418 M 387 M 387 M 387 M 387 M 371 M 371 M 371 M 371 M 294 M 294 M 294 M 294 M 177 M 177 M 177 M 177 M 125 M 125 M 125 M 125 M - - - -

Book Value

295 M 324 M 438 M 487 M 534 M 582 M 502 M 561 M 617 M 582 M 607 M 622 M 405 M 407 M 439 M 466 M 490 M 288 M 235 M 184 M 184 M 184 M 184 M 273 M 273 M 273 M 273 M 323 M 323 M 323 M 323 M 407 M 407 M 407 M 407 M 365 M 365 M 365 M 365 M 361 M 361 M 361 M 361 M 290 M 290 M 290 M 290 M 173 M 173 M 173 M 173 M 126 M 126 M 126 M 126 M - - - -

Total Shareholders Equity

295 M 324 M 438 M 487 M 534 M 582 M 502 M 561 M 617 M 582 M 607 M 622 M 405 M 407 M 439 M 466 M 490 M 288 M 235 M 184 M 184 M 184 M 184 M 273 M 273 M 273 M 273 M 323 M 323 M 323 M 323 M 407 M 407 M 407 M 407 M 365 M 365 M 365 M 365 M 361 M 361 M 361 M 361 M 290 M 290 M 290 M 290 M 173 M 173 M 173 M 173 M 126 M 126 M 126 M 126 M -6.44 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Prothena Corporation plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Amgen Amgen
AMGN
$ 350.62 0.81 % $ 189 B usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.8 2.35 % $ 133 M usaUSA
Altimmune Altimmune
ALT
$ 3.46 3.44 % $ 305 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 219.42 -1.11 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Incyte Corporation Incyte Corporation
INCY
$ 90.74 -0.04 % $ 17.7 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.62 2.22 % $ 35.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cullinan Management Cullinan Management
CGEM
$ 12.92 1.41 % $ 778 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 6.13 6.06 % $ 138 M franceFrance
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 16.76 -1.41 % $ 832 M britainBritain
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.23 -0.24 % $ 260 M israelIsrael
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 7.06 -7.47 % $ 860 K usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.27 2.83 % $ 419 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Denali Therapeutics Denali Therapeutics
DNLI
$ 21.23 5.26 % $ 3.49 B usaUSA
Longeveron Longeveron
LGVN
$ 0.95 -3.52 % $ 16.7 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.3 1.3 % $ 714 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA